These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18756070)

  • 21. Durable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.
    Maclean J; Breau RH; Scheida N; Malone S
    BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25199199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma.
    Beitler JJ; Makara D; Silverman P; Lederman G
    Am J Clin Oncol; 2004 Dec; 27(6):646-8. PubMed ID: 15577450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy.
    Han F; Zhao C; Huang SM; Lu LX; Huang Y; Deng XW; Mai WY; Teh BS; Butler EB; Lu TX
    Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):569-76. PubMed ID: 22209574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer.
    Staehler M; Haseke N; Stadler T; Nuhn P; Roosen A; Stief CG; Wilkowski R
    Urol Oncol; 2012; 30(3):290-3. PubMed ID: 20813555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy for renal-cell carcinoma.
    De Meerleer G; Khoo V; Escudier B; Joniau S; Bossi A; Ost P; Briganti A; Fonteyne V; Van Vulpen M; Lumen N; Spahn M; Mareel M
    Lancet Oncol; 2014 Apr; 15(4):e170-7. PubMed ID: 24694640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
    Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
    Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.
    Brinkmann OA; Bruns F; Gosheger G; Micke O; Hertle L
    World J Urol; 2005 Jul; 23(3):185-90. PubMed ID: 15838689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaginal metastasis of renal clear-cell cancer.
    Rehailia-Blanchard A; Morel A; Rancoul C; He MY; Magné N; Falkowski S
    Gulf J Oncolog; 2018 Jan; 1(26):67-71. PubMed ID: 29607827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palliative radiotherapy for lingual metastasis of renal cell carcinoma.
    Tomita T; Inouye T; Shinden S; Ogawa K; Mukai M
    Auris Nasus Larynx; 1998 May; 25(2):209-14. PubMed ID: 9673736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical delivery of intensity modulated conformal radiotherapy for relapsed or second-primary head and neck cancer using a multileaf collimator with dynamic control.
    De Neve W; De Gersem W; Derycke S; De Meerleer G; Moerman M; Bate MT; Van Duyse B; Vakaet L; De Deene Y; Mersseman B; De Wagter C
    Radiother Oncol; 1999 Mar; 50(3):301-14. PubMed ID: 10392816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases.
    Damast S; Wright J; Bilsky M; Hsu M; Zhang Z; Lovelock M; Cox B; Zatcky J; Yamada Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):819-26. PubMed ID: 20888133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of a volumetric modulated arc therapy treatment planning solution for kidney and adrenal stereotactic body radiation therapy.
    Sonier M; Chu W; Lalani N; Erler D; Cheung P; Korol R
    Med Dosim; 2016 Winter; 41(4):323-328. PubMed ID: 27745995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
    Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
    BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT.
    Hou JZ; Zeng ZC; Wang BL; Yang P; Zhang JY; Mo HF
    Jpn J Clin Oncol; 2016 Apr; 46(4):357-62. PubMed ID: 26802166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases.
    Jhaveri PM; Teh BS; Paulino AC; Blanco AI; Lo SS; Butler EB; Amato RJ
    Acta Oncol; 2012 May; 51(5):584-8. PubMed ID: 22248089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.